122 related articles for article (PubMed ID: 35838992)
1. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
Koudonas A; Papaioannou M; Kampantais S; Anastasiadis A; Hatzimouratidis K; Dimitriadis G
Medicine (Baltimore); 2022 Jul; 101(28):e29599. PubMed ID: 35838992
[TBL] [Abstract][Full Text] [Related]
2. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
Lin YL; Wang YP; Li HZ; Zhang X
Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
[TBL] [Abstract][Full Text] [Related]
4. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.
Dubrowinskaja N; Gebauer K; Peters I; Hennenlotter J; Abbas M; Scherer R; Tezval H; Merseburger AS; Stenzl A; Grünwald V; Kuczyk MA; Serth J
Cancer Med; 2014 Apr; 3(2):300-9. PubMed ID: 24464810
[TBL] [Abstract][Full Text] [Related]
6. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
7. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
Lin YL; Xie PG; Wang L; Ma JG
Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
[TBL] [Abstract][Full Text] [Related]
9. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.
Uyen TN; Sakashita K; Al-Kzayer LF; Nakazawa Y; Kurata T; Koike K
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27643535
[TBL] [Abstract][Full Text] [Related]
12. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
Joosten SC; Deckers IA; Aarts MJ; Hoeben A; van Roermund JG; Smits KM; Melotte V; van Engeland M; Tjan-Heijnen VC
Epigenomics; 2017 Sep; 9(9):1243-1257. PubMed ID: 28803494
[TBL] [Abstract][Full Text] [Related]
13. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
[TBL] [Abstract][Full Text] [Related]
14. GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.
Peters I; Gebauer K; Dubrowinskaja N; Atschekzei F; Kramer MW; Hennenlotter J; Tezval H; Abbas M; Scherer R; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2014 Apr; 31(4):1523-30. PubMed ID: 24549248
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
[TBL] [Abstract][Full Text] [Related]
17. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers.
Katzendorn O; Peters I; Dubrowinskaja N; Tezval H; Tabrizi PF; von Klot CA; Hennenlotter J; Lafos M; Kuczyk MA; Serth J
BMC Cancer; 2021 Apr; 21(1):444. PubMed ID: 33882870
[TBL] [Abstract][Full Text] [Related]
20. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]